Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
13 hedge funds and large institutions have $1.31M invested in Zivo Bioscience, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
27% more capital invested
Capital invested by funds: $1.03M → $1.31M (+$278K)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.5K |
| 2 |
BlackRock
New York
|
+$1.58K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$74 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$56 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.84K |
| 2 |
Morgan Stanley
New York
|
-$313 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $846K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $337K | +$29.5K | +1,589 | +10% |
|
|
3
BlackRock
New York
| $48.1K | +$1.58K | +85 | +3% |
|
4
Wells Fargo
San Francisco,
California
| $34.9K | – | – | – |
|
|
VCA
5
Verdence Capital Advisors
Hunt Valley,
Maryland
| $30.8K | – | – | – |
|
|
BCWM
6
Bartlett & Co Wealth Management
Cincinnati,
Ohio
| $3.08K | – | – | – |
|
|
BC
7
Bartlett & Co
Cincinnati,
Ohio
| $3K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $2.62K | -$2.84K | -153 | -52% |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1.94K | – | – | – |
|
|
BAM
10
Belpointe Asset Management
Reno,
Nevada
| $293 | – | – | – |
|
|
BCM
11
Bourgeon Capital Management
Darien,
Connecticut
| $96 | – | – | – |
|
|
12
Bank of America
Charlotte,
North Carolina
| $86 | +$56 | +3 | +150% |
|
|
13
Morgan Stanley
New York
| – | -$313 | -21 | Closed |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | +$74 | +4 | New |
|
ZIVO Hedge Fund Activity: Q1 2023 in Review
13 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q1 2023, worth a combined $1.31M — up 27% from $1.03M a quarter earlier.
Fund positioning in ZIVO was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $29.5K. The largest seller was UBS Group, cutting an estimated $2.84K.
- 13 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $1.31M of Zivo Bioscience, Inc. Common Stock stock for Q1 2023, up 27% quarter-over-quarter.
- 1 fund opened new Zivo Bioscience, Inc. Common Stock positions in Q1 2023 and 1 closed out, a net change of 0 holders.
- The largest Zivo Bioscience, Inc. Common Stock buyer in Q1 2023 was Vanguard Group, an estimated $29.5K added.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q1 2023 was UBS Group, an estimated $2.84K sold.
Based on aggregated 13F filings for Q1 2023.